Yahoo Finance

SK Life Science, Inc. to Present 10 Posters with New Cenobamate Data, Including a Late-Breaker, at the 2025 American Epilepsy Society (AES) Annual Meeting

PARAMUS, N.J. , Nov. 21, 2025 /PRNewswire/ -- SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., will ...
Morningstar

SK Life Science Presents Cenobamate Research at the 2024 American Epilepsy Society (AES) Annual Meeting

SK Life Science will also host the "Prioritizing Seizure Treatments Through Real-World Patient Case Studies Symposium," an expert led panel to advance the discussion regarding the unmet need for ...
FiercePharma

SK Life Science marks Purple Day for epilepsy awareness by highlighting patient support programs

SK Life Science is in a purple haze this week to help raise awareness around epilepsy. Since 2008, March 26 has marked Purple Day, a global day of recognition for the disease, during which people are ...
Morningstar

SK Life Science Launches Its Second National Ad, Continuing to Lead with the Only Direct-to-Consumer Commercial for an Anti-Seizure Drug in the U.S.

"Road to Reduction" Begins Airing Today Raising Awareness of XCOPRI® (cenobamate tablets) CV and the Journey to Seizure Management for People Living with Epilepsy PARAMUS, N.J., May 19, 2025 ...